Navigation Links
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Date:10/3/2007

dertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.

Contact:

MacroChem Corp.: Bernard Patriacca - VP/CFO

bpatriacca@macrochem.com

(781) 489-7310

Investor Relations: The Investor Relations Group, Inc.

Christine Berni/ Joseph Triunfo, (212) 825-3210

cberni@investorrelationsgroup.com

jtriunfo@investorrelationsgroup.com

Media:

Bill Douglass/ Michaela Heller, (212) 825-3210

bdouglass@investorrelationsgroup.com

mheller@investorrelationsgroup.com


'/>"/>
SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... least 2,000 Americans die from extreme heat or cold, floods ... stroke or sun stroke caused nearly one-third of more than ... the U.S. Centers for Disease Control and Prevention. Cold ... -- accounted for 63 percent of those weather-related deaths. The ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... DRE Medical — a leading medical equipment ... its Medical Trade Shows & Conventions Calendar Schedule ... equipment vendors. , The calendar is a continually-updating guide ... States and around the world. Hundreds of entries are ... always growing. , Information listed on each trade show ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of the Ensign™ ... that its Board of Directors has declared a quarterly cash dividend of ... April 30, 2010 to shareholders of record as of March 31, ... ...
... March 15 Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ... have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities ... ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and ... ...
... Spotlighting the importance of oral health care for expectant mothers, the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of dental treatment during ... ... ... ...
... at the University of Minnesota Medical School have discovered ... the hearts of Duchenne muscular dystrophy patients a ... children. The chemical, which Medical School scientists have termed ... heart muscle. When injected into the bloodstream, the molecular ...
... aspects of March Madness, offer tips to temper drawbacks , ... , , ... ... CHICAGO , March 15 ...
... ON , March 15 /PRNewswire-FirstCall/ - Nuvo Research ... the research and development of drug products that are delivered ... drug delivery technologies, and on the development of its immune ... the first patient in its European Phase 2 clinical trial ...
Cached Medicine News:Health News:The Ensign Group Declares Quarterly Dividend 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 3Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 4Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:Researchers discover chemical that may protect hearts of muscular dystrophy patients 2Health News:Experts Say It's Not So Bad to Go a Little Mad 2Health News:Experts Say It's Not So Bad to Go a Little Mad 3Health News:Experts Say It's Not So Bad to Go a Little Mad 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 2Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 3Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 5
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: